2008
Ten years of HER2-directed therapy: still questions after all these years
Krop IE, Winer EP. Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Research And Treatment 2008, 113: 207-209. PMID: 18463974, DOI: 10.1007/s10549-008-0041-2.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineClinical Trials, Phase III as TopicDeoxycytidineDisease-Free SurvivalDrug Delivery SystemsDrug Resistance, NeoplasmErbB ReceptorsFemaleFluorouracilForecastingHumansLapatinibNeoplasm ProteinsProtein Kinase InhibitorsQuinazolinesRandomized Controlled Trials as TopicReceptor, ErbB-2Trastuzumab
2004
New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
Lin NU, Winer EP. New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Research 2004, 6: 204. PMID: 15318926, PMCID: PMC549180, DOI: 10.1186/bcr919.Peer-Reviewed Original ResearchMeSH KeywordsAnticarcinogenic AgentsAntineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsErbB ReceptorsHumansReceptor Protein-Tyrosine KinasesSignal TransductionConceptsTyrosine kinase inhibitorsBreast cancerSmall molecule tyrosine kinase inhibitorsMolecule tyrosine kinase inhibitorsKinase inhibitorsErbB familyPredictive markerClinical dataReceptor signal transduction pathwaySmall molecule inhibitorsTumor sensitivityTumor growthReceptor tyrosine kinasesNew targetsCritical pathwaysMolecule inhibitorsCancerPotential crosstalkInhibitorsTyrosine kinaseSignal transduction pathwaysRational combinationBroad spectrumTransduction pathwaysMalignancy